Posts tagged: clinical
Phase I/II clinical trial of novel dialysate completed by Zytoprotec
Zytoprotec, a company developing drugs based on active cytoprotection, today announced the completion of a Phase I/II clinical trial with its lead product, PD-protec™. The product is developed to improve the treatment of patients with kidney failure.
New clinical trial to evaluate HSP90 inhibitor plus hormonal therapy for breast cancer
Pushed to the brink of survival, the hyper-driven cells of a cancerous tumor tap into an ancient system that has helped organisms cope with internal stresses and environmental challenges since life began. As an integral part of this system, heat shock protein 90 (HSP90) has been shown to help malignant ...
Benefits of ICS treatment vary among children with differing demographic, clinical characteristics
A further analysis of a previously published National Heart, Lung, and Blood Institute (NHLBI) funded study of children with mild persistent asthma reports the relative benefits of inhaled corticosteroid (ICS) treatment varies among children with differing demographic and clinical characteristics.
Canada should significantly increase its funding of randomized clinical trials
Large randomized controlled trials (RCTs) are critical for determining effectiveness of medical therapies, tests and procedures. Yet Canada provides scant support for these studies compared with other western countries, states an analysis in CMAJ ( Canadian Medical Association Journal ). Dr. Salim Yusuf, McMaster University ...
Clinical trials for Alzheimer’s disease preventative drug to begin early 2013
(Santa Barbara, Calif.) After an announcement by federal officials approving clinical trials for the drug Crenezumab, researchers searching for a way to treat Alzheimer's Disease are gearing up for a rare study that will allow them to test a therapy for a genetically predestined disease before its onset. ...
Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy
CAMBRIDGE, Mass. (May 22, 2012) Pushed to the brink of survival, the hyper-driven cells of a cancerous tumor tap into an ancient system that has helped organisms cope with internal stresses and environmental challenges since life began. As an integral part of this system, heat shock protein 90 ...
Data from EarlySense contact-free monitor clinical study presented at ATS conference
EarlySense, a market leader in proactive patient care solutions, announced today the results of a clinical study conducted at a Dignity Health Hospital. The data was presented today in a poster presentation titled: Effect Of Contactless Continuous Patient Monitoring In A Medical-Surgical Unit On Intensive Care Unit Transfers: A Controlled ...
Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy
(Whitehead Institute for Biomedical Research) A clinical trial involving collaboration between researchers at Whitehead Institute and Dana Farber Cancer Institute is now enrolling patients with recurrent or metastatic estrogen receptor-positive (ER+) breast cancer. In the developed world, approximately two-thirds of all breast cancer cases are ER+. The trial will test ...
Clinical Trials Needed To Test Non-Skeletal Benefits Of Vitamin D
The Endocrine Society's new scientific statement published online represents the first comprehensive evaluation of both the basic and clinical evidence related to the non-skeletal effects of vitamin D. The statement addresses current research regarding the associations of vitamin D with immune function, hypertension, stroke, skin conditions and maternal/fetal health. Vitamin ...
Clinical trials for Alzheimer’s disease preventative drug to begin early 2013
(University of California - Santa Barbara) After an announcement by federal officials approving clinical trials for the drug Crenezumab, researchers searching for a way to treat Alzheimer's Disease are gearing up for a rare study that will allow them to test a therapy for a genetically predestined disease -- before ...
Ceregene announces new data from CERE-120 clinical trial on Parkinson’s
Ceregene Inc., a biotechnology company developing treatments for neurodegenerative diseases such as Parkinson's disease, will present new data demonstrating long-term, biologically-active expression of neurturin, a nervous system growth factor delivered to the degenerating dopamine nerves in patients with Parkinson's disease following treatment with CERE-120.